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PhD,Andreas Huber, MD, Beat Mueller, MD, an
: Vitamin D deficiency has been associated with several
tcomes mainly in the outpatient setting. The objective of this
to examine the prevalence of vitamin D deficiency and its
n with risk of adverse clinical outcomes in a large prospective
medical inpatients.
llected clinical data and measured 25(OH)D levels in adult
atients upon hospital admission and followed them for 30
ression analyses adjusted for age, gender, comorbidities, and
ical diagnosis were performed to study the effect of vitamin D
on several hospital outcomes.
7 included patients, 1510 (35.47%) had 25(OH)D levels of 25
l/L (vitamin D insufficiency) and 797 (18.72%) had levels of
L (severe deficiency). Vitamin D insufficiency and severe
were associated (OR/HR, 95%CI) with an increased risk of
ortality (OR 1.70, 1.22–2.36 and 2.70, 1.22–2.36) and
length of stay (HR 0.88, 0.81–0.97 and 0.72, 0.65–0.81).
ficiency was associated with risk of falls (OR 1.77, 1.18–
aired Barthel index (OR 1.80, 1.42–2.28), and impairment in
life. Most associations remained robust after multivariate
t and in subgroups stratified by gender, age, comorbidities,
diagnoses (P for interaction >0.05).
comprehensive and large medical inpatient cohort, vitamin D
was highly prevalent and strongly associated with adverse
tcome. Interventional research is urgently needed to prove the
itamin D supplementation on these outcomes.
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CI = confidence interval, COPD = chronic obstructive
ry disease, LOS = length of hospital stay, OR = odds ratio.
INTRODUCTION
ans, vitamin D is acquired from transformation of
drocholesterol in the epidermis by exposure to ultra-
adiation, as well as dietary intake. The vitamin is then
zed in the liver to 25-hydroxyvitamin D (25(OH)D)
he kidneys to the active 1,25-dihydroxyvitamin D
)2D). It has pleiotropic effects since a majority
in the human body express vitamin D receptors.
)2Dmay interactwithover200genes thereby influencing
proliferation, differentiation, apoptosis, angiogenesis,
d renin production, bone and muscle metabolism, and
gmacrophagecathelicidinproduction.1–4 Inaccordance
e cellular effects, several clinical studies reported nega-
ts of vitamin D deficiency on mortality risk,5–8 cancer,9
cular,10 and infectious diseases11–13 among others.
ough there is still controversy about optimal levels of
D, a 25(OH)D serum concentration of less than
L is generally considered to indicate vitamin D insuf-
ith levels of<25nmol/L indicating severe deficiency.
a sufficient vitamin D status is mostly defined by its
for the prevention of bone diseases. Optimal levels,
may also depend on the patient population and
illness with recent evidence suggesting that higher
to 75–110 nmol/L) may positively influence medical
such as cancer or cardiovascular diseases.14–18
vitamin D deficiency is increasingly being prevalent
e19 with a prevalence of about 50% in the healthy
opulation in Switzerland20 in-depth knowledge of this
ing factor to disease has important public health implica-
ost of this research, however, has focused onoutpatients
cal data on medical inhospital patients are still scarce.
lose this gap, the aim of this prospective patient cohort
s to examine the associations of vitamin D deficiency
rent adverse clinical outcomes within different medical
ubgroups.
METHODS
esign and Setting
is an observational, prospective cohort study. Between
013 and February 2014 consecutive adult medical
were included upon hospital admission in the emer-lity-control TRIAGE project.
ptimize the triage and patient
ical emergencies.22
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Gra¨del et
2 | wwn observational quality control study, the Institutional
oard of the Canton of Aargau has approved the study
ed the need for informed consent (EK 2012/059).
Population and Management
ncludedconsecutive adult patientswithanacutemedical
king inhospitalcare.Surgical andpediatricpatientswere
. Initial vital signs and other clinical information such as
ographics, main medical diagnosis, and comorbidities
rded upon admission. Left over blood samples of all
ere collected and stored for later analyses including
ent of vitaminD levels.Clinical information andpatient
were assessed until hospital discharge and all patients
tacted by a structured phone interview 30 days after
in order to evaluate satisfaction with care, clinical and
l outcome measures, quality of life measures, perform-
tivities of daily living, as well as rehospitalization rates
ality. In case the patient could not be reached, family
or the general practitioner were contacted.22
iagnosis and Comorbidities
ents were divided according to their leading diagnosis
infections, cardiovascular diseases, metabolic dis-
ncer, neurological disorders, digestive tract diseases,
ry diseases, and other disease. Metabolic diseases
ncluded different diseases such as diabetes with hypo-
or hyperglycemia, hyperlipidemia, and severe electro-
rbances among others. We also defined the following
ity groups: congestive heart failure, chronic obstruc-
onary disease, dementia, diabetes mellitus, cancer, and
enal failure. Nutritional status was assessed using the
al Risk Screening 2002 within 48 hours after hospital
n. A risk of malnutrition was defined as a Nutritional
eening 2002 score of 3 points.23
e
primary outcome was 30 day all-cause mortality
during the hospital stay and by telephone interviews
.
ndary outcomes included functional impairment,
f life, length of hospital stay (LOS), readmission rate,
and fractures. Performance of daily living was
by the Barthel index.24 We defined functional impair-
Barthel index< 95 points. In order to assess quality of
sed the standardized measure of health questionnaire
including a descriptive system with 5 dimensions
, self-care, usual activities, pain/discomfort, and
epression), as well as a Europe specific summary
ue.25 These results were displayed as 2 levels, ‘‘impair-
or ‘‘no impairments.’’ The occurrence of falls and
was registered during hospitalization and in the 30
owing hospitalization by telephone interview.
ent of Vitamin D Levels and Definition of
iency
H)D levels were measured on left-over samples upon
n using a chemiluminescence immunoassay for the
ve determination of vitamin D. This method determines
3 as well as 25(OH)D2.We defined a normal vitamin D
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ncy as 25 to 50 nmol/L (10–20ng/mL), and a severe
y as <25nmol/L (<10ng/mL).26
LOS
insufficie
and 5 [2,
w.md-journal.com Copyrigcal Analysis
gorical variables are expressed as percentages and
r vice versa and continuous variables as medians
rtile ranges, 25th–75th percentiles), unless stated
. Frequency comparison was done by the Chi-square
all binary endpoints logistic models with odds ratios
d 95% confidence intervals (95%CIs) were used. For
ospital discharge, Cox regression models with hazard
re calculated. To adjust for possible confounding we
atistical models: model 1 for age and gender; model 2
gender, and comorbidities; model 3 for age, gender,
ities, and main diagnosis.
evaluated the association between vitamin D levels and
in the overall population as well as within different
d subgroups based on gender, age (cut-off 75 years), and
dical diagnosis. Evidence of effect modification within
groups was assessed by inclusion of interaction terms
atisticalmodels.AP value<0.05 (for a 2-sided test)was
d statistically significant. All statistical analyses were
d with STATA 12.1 (Stata corp, College Station, TX).
RESULTS
Population
257includedpatients,1510(35.47%)had25(OH)Dlevels
50nmol/L (vitamin D insufficiency) and 797 (18.72%)
s of<25nmol/L (severe deficiency). Baseline character-
he overall population stratified according to vitamin D
summarized in Table 1. Patients with an inadequate
level were older and were at higher risk of malnutrition.
ry analysis in patients with low vitamin D levels revealed
rum albumin levels, lower albumin corrected serum
evels and higher serum levels of creatinine. Also, patients
luded during winter and spring season had significantly
amin D levels as compared to summer and fall.
y Endpoint: Association of Vitamin D
rtality
h lower vitamin D levels we found a stepwise increase
ity of 3.4%, 5.6%, and 8.7% in patients with vitamin D
cy, insufficiency, and severe deficiency, respectively.
sion analysis, the unadjusted OR of 30-day mortality
in D insufficient patients compared to sufficient levels
e) was 1.70 (95%CI 1.22–2.36, P¼0.002) and in
deficient patients 2.70 (1.22–2.36, P<0.001). After
adjustment for demographics (model 1), comorbidities
), and medical diagnosis (model 3), the associations
significant with an OR of 1.49 (95%CI 1.03–2.14,
) for insufficient and 1.92 (95%CI 1.29–2.14,
1) for severely deficient patients in the fully adjusted
or detailed results see Table 2).
also investigated whether the association of vitamin D
y and 30 day mortality would differ among subgroups
ent demographics and main diagnoses (Appendix 1,
s.lww.com/MD/A941 and in Figure 1). For most
results were robust and no evidence of effect modi-
(P>0.05) was found, except for neurological dis-
r which the associations became weaker.
ary Endpoints: Vitamin D and Hospital
es
Medicine  Volume 95, Number 19, May 2016was stepwise increased in vitamin D sufficient,
nt, and severely deficient patients (3 [1, 6], 4 [1, 7],
9] days, respectively, P<0.001).
ht # 2016 Wolters Kluwer Health, Inc. All rights reserved.
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TABLE 1. Baseline Characteristics Categorized by Vitamin D Status
Characteristics Overall Normal Vitamin D Status Insufficiency Severe Deficiency P Value
N, % 4257 (100%) 1950 (45.8%) 1510 (35.5%) 797 (18.7%)
Age (median, IQR) 63 (46, 75) 61 (44, 74) 63 (46, 75) 68 (52, 79) <0.001
Male sex 2364 (55.5%) 1068 (54.8%) 869 (57.5%) 427 (53.6%) 0.12
NRS 3 378 (24.42%) 147 (22.1%) 121 (22.3%) 110 (32.4%) <0.001
Laboratory findings
Albumin (median, IQR) 37.7 (34, 40.7) 38.0 (34.6, 40.9) 37.7 (34.2, 40.5) 36.7 (31.5, 40.1) <0.001
Creatinine (median, IQR) 85 (70, 105) 84 (71, 102) 85 (69, 106) 87 (71, 117) 0.002
Calcium (median, IQR) 2.26 (2.19, 2.35) 2.26 (2.19, 2.35) 2.26 (2.18, 2.34) 2.28 (2.20, 2.37) <0.001
CRP (median, IQR) 17.9 (6.9, 70.1) 18 (7, 70) 16 (7, 62) 21 (7, 74) 0.25
Leucocytes (median, IQR) 8.5 (6.7, 11.0) 8.3 (6.7, 10.8) 8.6 (6.8, 11.1) 8.6 (6.6, 11.3) 0.34
Season
Spring 1698 (43.9%) 570 (33.5%) 724 (51.9%) 404 (52.3%) <0.001
Summer 1386 (35.8%) 849 (49.9%) 393 (28.2%) 144 (18.6%) <0.001
Fall 324 (8.4%) 180 (10.6%) 101 (7.2%) 43 (5.6%) <0.001
Winter 461 (11.9%) 101 (5.9%) 178 (12.8%) 182 (23.5%) <0.001
Main diagnosis
Infectious disease 610 (14.3%) 279 (14.3%) 204 (13.5%) 127 (15.9%) 0.29
Cardiovascular disease 947 (22.3%) 414 (21.2%) 354 (23.4%) 179 (22.5%) 0.3
Metabolic disorder 59 (1.4%) 14 (0.7%) 24 (1.6%) 21 (2.6%) <0.001
Cancer 217 (5.10%) 92 (4.7%) 85 (5.6%) 40 (5.0%) 0.48
Neurological disorder 1083 (25.44%) 525 (26.9%) 383 (25.4%) 175 (22.0%) 0.025
Digestive tract disease 458 (10.76%) 209 (10.7%) 155 (10.3%) 94 (11.8) 0.53
Pulmonary disease 157 (3.69%) 64 (3.3%) 62 (4.1%) 31 (3.9%) 0.42
Miscellaneous 726 (17.05%) 353 (18.1%) 243 (16.1%) 130 (16.3%) 0.25
Comorbidities
Diabetes 610 (14.33%) 211 (10.8%) 235 (15.6%) 164 (10.6%) <0.01
Tumor 638 (14.99%) 258 (13.2%) 235 (15.6%) 145 (18.2%) 0.003
Heart failure 250 (5.87%) 86 (4.4%) 89 (5.9%) 75 (9.4%) <0.001
COPD 204 (4.79%) 71 (3.6%) 70 (4.6%) 63 (7.9%) <0.001
Dementia 130 (3.05%) 48 (2.5%) 41 (2.7%) 41 (5.1%) <0.001
Renal failure 633 (14.87%) 225 (11.5%) 233 (15.6%) 175 (22.0%) <0.001
Obesity 520 (12.22%) 193 (9.9%) 220 (14.6%) 107 (13.4%) <0.001
Location after discharge
Home 1.645 (38.64%) 768 (39.4%) 573 (37.9%) 304 (38.1%) 0.66
Other hospital 226 (5.31%) 91 (4.7%) 83 (5.5%) 52 (6.5%) 0.13
Nursing home 172 (4.04%) 63 (3.2%) 55 (3.6%) 54 (6.8%) <0.001
Rehabilitation clinic 197 (4.63%) 87 (4.5%) 67 (4.4%) 43 (5.4%) 0.52
Inhospital death 115 (2.70%) 35 (1.8%) 51 (3.4%) 29 (3.6%) 0.003
Other or unknown 1.902 (44.68%) 906 (46.5%) 681 (45.1%) 315 (39.5%) 0.004
COPD¼ chronic obstructive pulmonary disease, CRP¼C-reactive protein, IQR¼ interquartile range, NRS¼ nutritional risk score, P¼P-value
are statist
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Copyrightdjusted hazard ratio for time to hospital discharge was
1–0.97, P¼0.007) and 0.72 (0.65–0.81, P< .001).
sociations remained mostly significant after multivari-
tment (Table 3). Similarly, we found a higher fre-
n impairment in activities of daily living (Barthel
5 points) based on vitamin D levels, with 11.3%,
nd 18.7% in vitamin D sufficient, insufficient, and
deficient patients, respectively. For severely deficient
the association was significant with an OR of 1.80
1.42–2.28, P<0.001), which remained robust after
nt. In subgroup analysis (Appendix 1, http://links.
/MD/A941 and Figures 2 and 3), there was evidence
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# 2016 Wolters Kluwer Health, Inc. All rights reserved.levels with 30-day hospital readmission rate overall,
fferent subgroups (no effect modifications).
actures and Quality of Life in the
Up
found a stepwise increase in reports of falls in the
deficient and severely deficient patients (3.1%, 3.4%,
), yet after adjustment these associations did not
ignificant. Also, the frequency of reported fractures
epend on vitamin D status (P¼0.69).
also observed an increase in reported impairment in
f life (defined by mobility, self-care, usual activity,
omfort, and anxiety/depression) in patients with a
itamin D deficiency compared to patients with
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FIGURE 3. Predictive value of vitamin D insufficiency and deficiency for 30-day readmission rate by patient subgroups.
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FIGURE 2. Predictive value of vitamin D insufficiency and deficiency for time to hospital discharge by patient subgroups.
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FIGURE 5. Predictive value of vitamin D insufficiency and deficiency for falls by patient subgroup.
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FIGURE 4. Predictive value of vitamin D insufficiency and deficiency for functional impairment by patient subgroups as measured by the
Barthel index.
Gra¨del et al Medicine  Volume 95, Number 19, May 2016
8 | www.md-journal.com Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
significan
patients.5
be adequ
free fract
tion, bec
represent
measurem
challengi
Vita
matory a
physiopa
comes w
stitution
status.59
populatio
recomme
ation are
keletal o
conducte
falls and
there is
reporting
The
defined c
justifying
order to
daily liv
facilitate
measured
bias. Ne
considere
and resu
Although
eliminate
encing o
were not
methodo
liquid ch
dard, as i
cence im
method
equipmen
laborator
chronicit
ing the r
come. M
hypothes
Our
shows a
the medi
different
different
ized cont
suppleme
an acute
REFEREN
1. Bouill
perspe
974–9
u P
tam
06;
agpa
cept
eLu
ncti
89S
ow
use
serv
14;3
arlan
orta
alth
elam
vels
ed.
tterm
seas
ess
even
tterm
s. 2
noah
berc
08;3
lasse
ass
350
15;1
atki
soci
seas
iova
tal c
iova
k o
ed.
obni
rum
l-cau
08;1
rma
dro
nsio
lz S
soci
ome
itha
term
07–
scho
nao¨
voo¨
acL
man
36–
Medicine
Copyrighttly lower albumin level in vitamin D deficient
5,56 Thus, measuring total serum 25(OH)D may not
ate to assess vitamin D status during acute illness. The
ion of 25(OH)D may be a more accurate representa-
ause it is not influenced by albumin levels and it
s the physiologically important fraction. However,
ent of the bioavailable fraction is technically more
ng.55,57
min D has also been suggested to have antiinflam-
nd antiproliferative properties.4,58 These effects may
thologically explain the increase in adverse out-
ith deficient vitamin D status and call for the sub-
of patients in order to correct impaired vitamin D
However, without interventional data in this patient
n such conclusions may not be warranted. Current
ndations for vitamin D screening and supplement-
based on data regarding the benefits for musculos-
utcomes. Many large observational studies have been
d on the benefits of vitamin D supplementation on
fractures.60,61 Still, even for musculoskeletal health
remaining ambiguity with recent randomized trials
conflicting results.62,63
study has several strengths: we studied a large, well-
ohort with a heterogeneous patient population, thus
the validity of our data in the general population. In
assess impairments in quality of life and activities of
ing we used standardized tools, which furthermore
the comparison of our results. Vitamin D levels were
in a consecutive sample limiting the risk of selection
vertheless, some limitations of our study should be
d. It was a single-center study including Swiss patients
lts may not be generalizable to other countries.
we adjusted for potential confounders, we cannot
the possibility of residual confounding factors influ-
ur results. For example, parathyroid hormone levels
available. Also, there is controversy regarding the best
logy for measuring 25(OH)D. High-performance
romatography is generally considered the gold-stan-
t is more accurate and reliable than the chemilumines-
munoassay we used in our study. However, this
is time and labor intensive and requires expensive
t, thus making it unsuitable to high-capacity clinical
ies.64,65 In addition, we did not have data available on
y of disease which may be an important factor explain-
elationship of low vitamin D levels and adverse out-
ost importantly, as an observational study it is more
is generating and does not address causality.
CONCLUSION
study confirms results from previous studies and
high prevalence of inadequate vitamin D status in
cal inpatient population with strong associations with
adverse medical outcomes and robust results among
medical diagnosis subgroups. High-quality random-
rolled studies are needed to assess whether vitamin D
ntation could improve the course and recovery from
illness in the medical inpatient setting.
CES
2. Li
vi
20
3. N
re
4. D
fu
16
5. Ch
ca
ob
20
6. G
m
he
7. M
le
M
8. Zi
di
9. N
pr
10. Zi
Re
11. N
tu
20
12. K
be
<
20
13. W
as
di
14. G
ec
15. G
ris
M
16. D
se
al
20
17. Fo
hy
te
18. Pi
as
w
19. M
de
18
20. Bi
Er
Be
21. M
hu
15
 Volume 95, Number 19, May 2016on R, Bischoff-Ferrari H, Willett W. Vitamin D and health:
ctives from mice and man. J Bone Miner Res. 2008;23:
79.
22. Schue
hospit
triage
# 2016 Wolters Kluwer Health, Inc. All rights reserved.T, Stenger S, Li H, et al. Toll-like receptor triggering of a
in D-mediated human antimicrobial response. Science.
311:1770–1773.
l S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D
or ligands. Endocr Rev. 2005;26:662–687.
ca HF. Overview of general physiologic features and
ons of vitamin D. Am J Clin Nutr. 2004;80(6 Suppl):
–1696S.
dhury R, Kunutsor S, Vitezova A, et al. Vitamin D and risk of
specific death: systematic review and meta-analysis of
ational cohort and randomised intervention studies. BMJ.
48:g1903.
d CF, Kim JJ, Mohr SB, et al. Meta-analysis of all-cause
lity according to serum 25-hydroxyvitamin D. Am J Public
. 2014;104:e43–50.
ed ML, Michos ED, Post W, et al. 25-hydroxyvitamin D
and the risk of mortality in the general population. Arch Inter
2008;168:1629–1637.
ann A, Prokop S. The role of vitamin D for cardiovascular
e and overall mortality. Adv Exp Med Biol. 2014;810:106–119.
RA, Miller DD, Li W. The role of vitamin D in cancer
tion. Chin J Nat Med. 2015;13:481–497.
ann A. Vitamin D and cardiovascular disease. Anticancer
014;34:4641–4648.
am KE, Clarke A. Low serum vitamin D levels and
ulosis: a systematic review and meta-analysis. Int J Epidemiol.
7:113–119.
n KM, Fairley CK, Chen M, et al. Vitamin D deficiency may
ociated with a more rapid decline in CD4 cell count to
cells/muL in untreated HIV-infected adults. Curr HIV Res.
3:517–523.
ns RR, Lemonovich TL, Salata RA. An update on the
ation of vitamin D deficiency with common infectious
es. Can J Physiol Pharmacol. 2015;93:363–368.
nnucci E. Epidemiological evidence for vitamin D and color-
ancer. J Bone Miner Res. 2007;22(Suppl 2):V81–85.
nnucci E, Liu Y, Hollis BW, et al. 25-hydroxyvitamin D and
f myocardial infarction in men: a prospective study. Arch Inter
2008;168:1174–1180.
g H, Pilz S, Scharnagl H, et al. Independent association of low
25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with
se and cardiovascular mortality. Arch Inter Med.
68:1340–1349.
n JP, Giovannucci E, Holmes MD, et al. Plasma 25-
xyvitamin D levels and risk of incident hypertension. Hyper-
n. 2007;49:1063–1069.
, Henry RM, Snijder MB, et al. 25-Hydroxyvitamin D is not
ated with carotid intima-media thickness in older men and
n. Calcif Tissue Int. 2009;84:423–424.
l A, Wahl DA, Bonjour JP, et al. Global vitamin D status and
inants of hypovitaminosis D. Osteoporos Int. 2009;20:
1820.
ff-Ferrari HA. Empfehlungen der Eidgeno¨ssischen
hrungskommis-sion zur Vitamin-D-Zufuhr fuo¨r die Schweizer
lkerung. Swiss Med Forum. 2012;12:775–778.
aughlin J, Holick MF. Aging decreases the capacity of
skin to produce vitamin D3. J Clin Invest. 1985;76:
1538.
Vitamin D Deficiency in Medical Inpatientstz P, Hausfater P, Amin D, et al. Optimizing triage and
alization in adult general medical emergency patients: the
project. BMC Emerg Med. 2013;13:12.
www.md-journal.com | 9
23. Kondr
screen
contro
24. Maho
MD S
25. EuroQ
health
26. Preven
Tech R
27. Thom
D in m
28. Feder
safety
Repor
2012.
29. Abdel
and im
infecti
30. Anty
hydro
bacter
2014;5
31. Remm
vitami
outcom
2012;5
32. Leow
and ou
2011;1
33. Lange
conce
patien
34. Amrei
U-sha
morta
1461–
35. Khalil
status
follow
2012;1
36. Amrei
associ
illness
37. Braun
25-hy
Care M
38. McKi
vitami
Assoc
39. Aygen
insuff
Care R
40. Hu J,
hormo
prospe
41. Su LX
D for
patien
42. Venka
associ
Care.
etz
com
soci
elard
ger
arke
auc
spit
sult
13;1
iebz
tien
ncti
llica
dro
pula
11;9
iggin
vita
Pare
ang
depe
soci
n d
tus
hort
inde
d se
fecti
urai
twe
eam
ahl
urse
rishn
e as
it C
kle
25-
e vi
86;6
kle
vels
dro
ema
cond
an i
patie
un
mu
ysio
uada
pe
n. J
scho
even
eta-a
schoff-Ferrari HA, Willett WC, Wong JB, et al. Prevention of
Gra¨del et
10 | wup J, Rasmussen HH, Hamberg O, et al. Nutritional risk
ing (NRS 2002): a new method based on an analysis of
lled clinical trials. Clin Nutr. 2003;22:321–336.
ney FI, Barthel DW. Functional evaluation: the Barthel index.
tate Med J. 1965;14:61–65.
ol G. EuroQol – a new facility for the measurement of
-related quality of life. Health Policy. 1990;16:199–208.
tion and management of osteoporosis. World Health Organ
ep Ser. 2003;921:1–164back cover.
as MK, Lloyd-Jones DM, Thadhani RI, et al. Hypovitaminosis
edical inpatients. N Engl J Med. 1998;338:777–783.
al Commission for Nutrition: Vitamin D deficiency: Evidence,
, and recommendations for the Swiss Population. Expert
t of the FCN. Zurich. Federal Office for Public Health.
fatah M, Nayfe R, Moftakhar B, et al. Low vitamin D level
pact on severity and recurrence of Clostridium difficile
ons. J Invest Med. 2015;63:17–21.
R, Tonohouan M, Ferrari-Panaia P, et al. Low levels of 25-
xy vitamin d are independently associated with the risk of
ial infection in cirrhotic patients. Clin Transl Gastroenterol.
:e56.
elts HH, van de Garde EM, Meijvis SC, et al. Addition of
n D status to prognostic scores improves the prediction of
e in community-acquired pneumonia. Clin Infect Dis.
5:1488–1494.
L, Simpson T, Cursons R, et al. Vitamin D, innate immunity
tcomes in community acquired pneumonia. Respirology.
6:611–616.
N, Litonjua AA, Gibbons FK, et al. Pre-hospital vitamin D
ntration, mortality, and bloodstream infection in a hospitalized
t population. Am J Med. 2013;126:640e619–e627.
n K, Quraishi SA, Litonjua AA, et al. Evidence for a
ped relationship between prehospital vitamin D status and
lity: a cohort study. J Clin Endocrinol Metab. 2014;99:
1469.
i H, Talasaz AH, Salarifar M. Serum vitamin D concentration
and its correlation with early biomarkers of remodeling
ing acute myocardial infarction. Clin Res Cardiol.
01:321–327.
n K, Zajic P, Schnedl C, et al. Vitamin D status and its
ation with season, hospital and sepsis mortality in critical
. Crit Care. 2014;18:R47.
A, Chang D, Mahadevappa K, et al. Association of low serum
droxyvitamin D levels and mortality in the critically ill. Crit
ed. 2011;39:671–677.
nney JD, Bailey BA, Garrett LH, et al. Relationship between
n D status and ICU outcomes in veterans. J Am Med Dir
. 2011;12:208–211.
cel G, Turkoglu M, Tuncel AF, et al. Is vitamin d
iciency associated with mortality of critically ill patients? Crit
es Pract. 2013;2013:856747.
Luo Z, Zhao X, et al. Changes in the calcium-parathyroid
ne-vitamin d axis and prognosis for critically ill patients: a
ctive observational study. PloS One. 2013;8:e75441.
, Jiang ZX, Cao LC, et al. Significance of low serum vitamin
infection risk, disease severity and mortality in critically ill
ts. Chin Med J. 2013;126:2725–2730.
43. Pl
in
as
44. H
in
M
45. Be
ho
Re
20
46. K
pa
fu
47. Pe
hy
po
20
48. H
of
J
49. W
in
as
50. va
sta
co
51. G
an
in
52. Q
be
str
53. D
co
54. K
th
Cr
55. Bi
of
th
19
56. Bi
le
hy
57. Pr
se
th
in
58. Ch
im
Ph
59. G
Ty
tio
60. Bi
pr
m
61. Bi
altram S, Chilimuri S, Adrish M, et al. Vitamin D deficiency is
ated with mortality in the medical intensive care unit. Crit
2011;15:R292.
nonve
meta-a
2009;1
ww.md-journal.com CopyrigMW, Terkamp C, Schumacher U, et al. Vitamin D deficiency
munity-acquired pneumonia: low levels of 1,25(OH)2 D are
ated with disease severity. Respir Res. 2014;15:53.
L, Mateus-Hamdan L, Beauchet O, et al. Hypovitaminosis D
iatric acute care unit: a biomarker of longer length of stay. Dis
rs. 2013;35:525–529.
het O, Launay C, de Decker L, et al. Who is at risk of long
al stay among patients admitted to geriatric acute care unit?
s from a prospective cohort study. J Nutr Health Aging.
7:695–699.
ak GM, Moore NL, Margolis S, et al. Vitamin D status of
ts admitted to a hospital rehabilitation unit: relationship to
on and progress. Am J Phys Med Rehabil. 2007;86:435–445.
ne AJ, Wysocki NM, Mallinson TR, et al. Prevalence of 25-
xyvitamin D deficiency in the acute inpatient rehabilitation
tion and its effect on function. Arch Phys Med Rehabil.
2:705–711.
s DM, Wischmeyer PE, Queensland KM, et al. Relationship
min D deficiency to clinical outcomes in critically ill patients.
nt Enter Nutr. 2012;36:713–720.
WJ, Gray S, Sison C, et al. Low vitamin D level is an
ndent predictor of poor outcomes in Clostridium difficile-
ated diarrhea. Ther Adv Gastroenterol. 2014;7:14–19.
er Wilden GM, Fagenholz PJ, Velmahos GC, et al. Vitamin D
and severity of Clostridium difficile infections: a prospective
study in hospitalized adults. J Parent Enter Nutr. 2014.
AA, Camargo CA Jr, Shapiro NI. Vitamin D insufficiency
psis severity in emergency department patients with suspected
on. Acad Emerge Med. 2011;18:551–554.
shi SA, Litonjua AA, Moromizato T, et al. Association
en prehospital vitamin D status and hospital-acquired blood-
infections. Am J Clin Nutr. 2013;98:952–959.
B, Schiodt FV, Kiaer T, et al. Serum Gc-globulin in the early
of multiple trauma. Crit Care Med. 1998;26:285–289.
an A, Ochola J, Mundy J, et al. Acute fluid shifts influence
sessment of serum vitamin D status in critically ill patients.
are. 2010;14:R216.
DD, Gee E, Halloran B, et al. Assessment of the free fraction
hydroxyvitamin D in serum and its regulation by albumin and
tamin D-binding protein. J Clin Endocrinol Metab.
3:954–959.
DD, Halloran BP, Gee E, et al. Free 25-hydroxyvitamin D
are normal in subjects with liver disease and reduced total 25-
xyvitamin D levels. J Clin Invest. 1986;78:748–752.
or MO, Alves GV, Crossetti LB, et al. Hyperparathyroidism
ary to hypovitaminosis D in hypoalbuminemic is less intense
n normoalbuminemic patients: a prevalence study in medical
nts in southern Brazil. Endocrine. 2004;24:47–53.
RF, Liu PT, Modlin RL, et al. Impact of vitamin D on
ne function: lessons learned from genome-wide analysis. Front
l. 2014;5:151.
rrama-Lopez AL, Valdes-Ramos R, Martinez-Carrillo BE.
2 diabetes, PUFAs, and vitamin D: their relation to inflamma-
Immunol Res. 2014;2014:860703.
ff-Ferrari HA, Dawson-Hughes B, Staehelin HB, et al. Fall
tion with supplemental and active forms of vitamin D: a
nalysis of randomised controlled trials. BMJ. 2009;339:b3692.
Medicine  Volume 95, Number 19, May 2016rtebral fractures with oral vitamin D and dose dependency: a
nalysis of randomized controlled trials. Arch Inter Med.
69:551–561.
ht # 2016 Wolters Kluwer Health, Inc. All rights reserved.
62. Hanse
D insu
trial. J
63. Bischo
high-d
a rand
ellm
tus:
ne. 2010;5:e11555.
Medicine
Copyrightn KE, Johnson RE, Chambers KR, et al. Treatment of vitamin
fficiency in postmenopausal women: A randomized clinical
AMA Intern Med. 2015;175:1612–1621.
64. Sn
sta
O
 Volume 95, Number 19, May 2016ff-Ferrari HA, Dawson-Hughes B, Orav EJ, et al. Monthly
ose vitamin D treatment for the prevention of functional decline:
omized clinical trial. JAMA Inter Med. 2016;176:175–183.
65. Zerwe
2008;
# 2016 Wolters Kluwer Health, Inc. All rights reserved.an G, Melhus H, Gedeborg R, et al. Determining vitamin D
a comparison between commercially available assays. PloS
Vitamin D Deficiency in Medical Inpatientskh JE. Blood biomarkers of vitamin D status. Am J Clin Nutr.
87:1087S–1091S.
www.md-journal.com | 11
